Atossa Genetics Inc (NASDAQ:ATOS) Could Burn Your Long Portfolio After More Shorts

May 17, 2018 - By Vivian Park

Atossa Genetics Inc. (NASDAQ:ATOS) Logo

The stock of Atossa Genetics Inc (NASDAQ:ATOS) registered an increase of 39.14% in short interest. ATOS’s total short interest was 380,700 shares in May as published by FINRA. Its up 39.14% from 273,600 shares, reported previously. With 869,700 shares average volume, it will take short sellers 0 days to cover their ATOS’s short positions.

The stock decreased 6.43% or $0.25 during the last trading session, reaching $3.64. About 87,301 shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 57.26% since May 17, 2017 and is downtrending. It has underperformed by 68.81% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $9.65 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Atossa Genetics Inc. (NASDAQ:ATOS) Ratings Coverage

Among 2 analysts covering Atossa Genetics (NASDAQ:ATOS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Atossa Genetics had 2 analyst reports since January 26, 2018 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Friday, January 26.

More notable recent Atossa Genetics Inc. (NASDAQ:ATOS) news were published by: Globenewswire.com which released: “Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth” on May 03, 2018, also Nasdaq.com with their article: “Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study” published on April 30, 2018, Seekingalpha.com published: “Atossa Genetics’ (ATOS) Corporate Conference Call Transcript” on May 17, 2018. More interesting news about Atossa Genetics Inc. (NASDAQ:ATOS) were released by: Nasdaq.com and their article: “Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical …” published on May 15, 2018 as well as Benzinga.com‘s news article titled: “36 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: May 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.